TABLE 2.
Grade 2 and greater toxicities related (possibly, probably, or definitely) to palbociclib and/or ganitumab therapy (n = 10).
| Toxicity type | Maximum toxicity grade n (%) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Hematologic toxicity | |||
| Anemia | 2 (20%) | 0 (0%) | 0 (0%) |
| Lymphocyte count decreased | 3 (30%) | 0 (0%) | 1 (10%) |
| Neutrophil count decreased | 1 (10%) | 5 (50%) | 3 (30%) |
| Platelet count decreased | 2 (20%) | 4 (40%) | 1 (10%) |
| White blood cell decreased | 1 (10%) | 7 (70%) | 0 (0%) |
| Non‐hematologic toxicity | |||
| Fatigue | 1 (10%) | 0 (0%) | 0 (0%) |
| Infusion related reaction | 1 (10%) | 0 (0%) | 0 (0%) |
| Hypophosphatemia | 1 (10%) | 0 (0%) | 0 (0%) |
| Metabolism and nutrition disorders—vitamin D deficiency | 1 (10%) | 0 (0%) | 0 (0%) |
| Hypertension | 0 (0%) | 1 (10%) | 0 (0%) |
Note: Adverse events were reported at the maximum grade per type per patient, regardless of cycle in which the adverse events were observed.